Please select a Capability in order to start your service request.
ChloraPrep 1 mL Applicator Provides Additional Option to Proven Portfolio of Patient Skin Preparation ProductsJul 31, 2014
SAN DIEGO, July 31, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, today announced the launch of its ChloraPrep® 1 mL applicator, the newest addition to the ChloraPrep line of preoperative skin preparation products.
ChloraPrep 1 mL provides clinicians with a preferred applicator design and the same formulation as all other ChloraPrep applicators but in a new 1 mL size. The new size is ideal for procedures with an application area approximately 2.5 inches by 2.5 inches or smaller.
"The new ChloraPrep 1 mL applicator is an excellent extension of our ChloraPrep family of products, using the same formulation clinicians have come to know and trust," said Jan Creidenberg, vice president and general manager of Infection Prevention for CareFusion. "We continue to extend our skin prep leadership through our commitment to innovation and new product development to better meet our customers' needs."
With its unique delivery system and winged activation design, the 1 mL applicator is easy to use and can help promote aseptic technique and best practices. ChloraPrep skin prep products have been proven to be more effective than povidone-iodine at reducing microorganisms on the skin that may cause infection.1,2,3 ChloraPrep chlorhexidine products also have a low incidence of irritation and maintain their antimicrobial effectiveness in the presence of blood, unlike iodine-based products.4
Clinicians interested in trying the new ChloraPrep 1 mL applicator can visit carefusion.com/SmallButBig and fill out a form to request a sample.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.
1 Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery. J Bone Joint Surg Am. 2009;91(8):1949–1953.
2 Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980–985.
3 Adler MT, Brigger KR, Bishop KD, Mastrobattista JM. Comparison of bactericidal properties of alcohol-based chlorhexidine versus povidone-iodine prior to amniocentesis. Am J Perinatol. 2012;29(6):455–458. Epub 2012 Mar 7.
4 Denton, G. Chlorhexidine. In Block, SS. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:321–336.